{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:26:38Z","timestamp":1788852398906,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic syndrome caused by phosphaturic mesenchymal tumors (PMTs). FGF23, which is overproduced by PMTs, causes hypophosphatemia and osteomalacia, ultimately leading to multiple insufficiency fractures, which are the cause of TIO symptoms. Therefore, recovery from TIO symptoms often takes several months. Due to its paracrine effects, even minuscule amounts of residual PMT can cause treatment to fail. To further compound this, the most confident methods for residual PMTs, serum FGF23 level and 68Ga DOTA-based PET\/CT, are not readily available. For these reasons, there is currently no established method for early prediction of TIO treatment outcomes after surgery. This study focuses on mineral metabolism and bone turnover markers to identify a clinically practical and readily available biomarker that can predict TIO treatment outcomes. Methods: During treatment, we analyzed repeated measurements during treatment of mineral metabolism and bone turnover markers for 19 cases of TIO\u2014Ca, inorganic phosphate (Pi), parathyroid hormone (PTH), 25-hydroxyvitamin D, alkaline phosphatase, Procollagen 1 N-terminal Polypeptide, and \u03b2-CrossLaps\u2014in relation to treatment outcomes. We selected predictive marker candidates from among these markers by analyzing their patterns of change during treatment based on three viewpoints\u2014association with (1) cure status, (2) time after treatment, and (3) the interaction effects between (1) and (2) using Linear Mixed Model analysis. We also validated the predictive performance of the selected candidates. Results: In long-term follow-up, only serum Pi and PTH levels were significantly associated with all three metrics mentioned above, suggesting that their patterns of change reflect the clinical course and results of TIO treatment. Pi was the only marker that displayed the same associations during short-term follow-up (two weeks and six weeks after treatment), suggesting that it is a rapidly responsive marker. The serum Pi level two weeks after treatment (Odds Ratio = 7.314, p = 0.028, AUC value of 0.907) and the normalization of Pi at two weeks post-treatment (Relative Risk = 9.975, p = 0.010; sensitivity = 100.0% [95% Confidence Interval (CI) 0.860 to 1.000], specificity = 60.0% [95% CI, 0.208 to 0.600]) were both significantly associated with a complete cure. Conclusions: Serum Pi is a fast, simple, and highly sensitive marker that can replace serum FGF23 and 68Ga DOTA-based PET\/CT in clinical practice for predicting a complete cure of TIO within two weeks of surgery.<\/jats:p>","DOI":"10.3390\/jcm14217870","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:02:03Z","timestamp":1762419723000},"page":"7870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum Phosphorus Is a Fast and Highly Sensitive Marker Predictive of a Complete Cure of Tumor-Induced Osteomalacia"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-1944","authenticated-orcid":false,"given":"Seung Hyun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-391X","authenticated-orcid":false,"given":"Young Han","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8246-1956","authenticated-orcid":false,"given":"NamKi","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7428-5999","authenticated-orcid":false,"given":"Sungjoon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-5638","authenticated-orcid":false,"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e3428","DOI":"10.1210\/clinem\/dgac253","article-title":"Tumor-induced Osteomalacia: A Systematic Review and Individual Patient\u2019s Data Analysis","volume":"107","author":"Rendina","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/ki.2011.27","article-title":"Phosphate and FGF-23","volume":"79","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00256-018-3014-5","article-title":"Imaging features of phosphaturic mesenchymal tumors","volume":"48","author":"Broski","year":"2019","journal-title":"Skelet. Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1177\/02841851231160086","article-title":"Imaging characteristics of phosphaturic mesenchymal tumors","volume":"64","author":"Gupta","year":"2023","journal-title":"Acta Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1210\/clinem\/dgac096","article-title":"Diagnostic Utility of Somatostatin Receptor 2A Immunohistochemistry for Tumor-induced Osteomalacia","volume":"107","author":"Lee","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12149-021-01575-x","article-title":"Diagnostic performance of (68)Ga-DOTATOC PET\/CT in tumor-induced osteomalacia","volume":"35","author":"Kato","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/RLU.0000000000000854","article-title":"68Ga DOTATATE PET\/CT is an Accurate Imaging Modality in the Detection of Culprit Tumors Causing Osteomalacia","volume":"40","author":"Zhang","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3349\/ymj.2017.58.5.981","article-title":"Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23","volume":"58","author":"Lee","year":"2017","journal-title":"Yonsei Med. J."},{"key":"ref_9","first-page":"627","article-title":"Burosumab for the Treatment of Tumor-Induced Osteomalacia","volume":"36","author":"Miller","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"bvab099","DOI":"10.1210\/jendso\/bvab099","article-title":"Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience","volume":"5","author":"Dahir","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-015-0496-3","article-title":"Surgical treatment of tumor-induced osteomalacia: A retrospective review of 40 cases with extremity tumors","volume":"16","author":"Sun","year":"2015","journal-title":"BMC Musculoskelet. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/os.14105","article-title":"Orthopedic Surgical Treatment of Patients with Tumor-induced Osteomalacia Located in the Hip Bones: A Retrospective Analysis of 10 Years in a Single Center","volume":"16","author":"Liu","year":"2024","journal-title":"Orthop. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/jbmr.4620","article-title":"Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance","volume":"37","author":"Hidaka","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Shan, C., Wei, Z., Li, S., Zhang, Z., Yue, H., Yu, W., Yang, Q., and Zhang, Z. (2025). Postoperative outcome and clinical management of tumor-induced osteomalacia: A single-center retrospective cohort study on 117 patients. Osteoporos. Int., 1\u201312.","DOI":"10.1007\/s00198-025-07527-9"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2106\/JBJS.N.01299","article-title":"Surgical Treatments of Tumor-Induced Osteomalacia Lesions in Long Bones: Seventeen Cases with More Than One Year of Follow-up","volume":"97","author":"Wang","year":"2015","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sipos, D., Debreczeni-M\u00e1t\u00e9, Z., Ritter, Z., Freihat, O., Simon, M., and Kov\u00e1cs, \u00c1. (2024). Complex Diagnostic Challenges in Glioblastoma: The Role of 18F-FDOPA PET Imaging. Pharmaceuticals, 17.","DOI":"10.3390\/ph17091215"},{"key":"ref_17","first-page":"64","article-title":"Clinical application of (18)F-DOPA PET\/TC in pediatric patients","volume":"11","author":"Masselli","year":"2021","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/clinchem\/29.5.751","article-title":"A reference method for measurement of alkaline phosphatase activity in human serum","volume":"29","author":"Tietz","year":"1983","journal-title":"Clin. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/cam4.1022","article-title":"Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma","volume":"6","author":"Kim","year":"2017","journal-title":"Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.3903","article-title":"Nonremission and Recurrent Tumor-Induced Osteomalacia: A Retrospective Study","volume":"35","author":"Li","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101772","DOI":"10.1016\/j.bonr.2024.101772","article-title":"Tumor-induced osteomalacia: A systematic literature review","volume":"21","author":"Maneiro","year":"2024","journal-title":"Bone Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-024-01249-6","article-title":"Long-Term Follow-Up Data of Tumor-Induced Osteomalacia Managed with Surgery and\/or Radiofrequency Ablation from a Single Center","volume":"115","author":"Memon","year":"2024","journal-title":"Calcif. Tissue Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clinimag.2019.04.007","article-title":"Tumor-induced osteomalacia\u2014Current imaging modalities and a systematic approach for tumor localization","volume":"56","author":"Rayamajhi","year":"2019","journal-title":"Clin. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/joim.13593","article-title":"Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia","volume":"293","author":"Minisola","year":"2023","journal-title":"J. Intern. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:35:13Z","timestamp":1762421713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":24,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14217870"],"URL":"https:\/\/doi.org\/10.3390\/jcm14217870","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}